Literature DB >> 36253533

Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review.

Alison Luk Young1, Aalya Imran2, Michael J Spoelma3, Rachel Williams4,5, Katherine M Tucker4,5, Jane Halliday6,7, Laura E Forrest8,9, Claire E Wakefield10,11, Phyllis N Butow12.   

Abstract

Interventions to assist family communication about inherited cancer risk have the potential to improve family cancer outcomes. This review aimed to evaluate the efficacy of proband-mediated interventions employed within genetics clinics to increase disclosure of genetic risk to at-risk relatives. MEDLINE, Embase, CINAHL, PubMed and PsycINFO were searched for publications between 1990-2020. The quality of studies was assessed. From 5605 records reviewed, 9 studies (4 randomised control trials and 5 cohort studies) were included involving families with BRCA1, BRCA2 and Lynch syndrome. Intervention delivery modes included genetic counselling with additional telephone or in-person follow-up, letters, videos, and decision aids. The percentages of at-risk relatives informed by the proband about their risk ranged from 54.0% to 95.5% in the intervention or family-mediated comparison group. Of those who were informed, 24.4-60.0% contacted a genetics clinic and 22.8-76.2% had genetic testing after they were counselled at a genetics clinic. Significant differences between intervention and control group were reported on all three outcomes by one study, and with relatives contacting a genetics clinic by another study. The studies suggest but do not conclusively show, that tailored genetic counselling with additional follow-up can increase both the proportion of informed relatives and relatives who contact the genetics clinic. With the increase in germline testing, interventions are required to consider the family communication process and address post-disclosure variables (e.g., relative's perceptions, emotional reactions) through engagement with probands and relatives to maximise the public health benefit of identifying inherited cancer risk in families.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36253533     DOI: 10.1038/s41431-022-01200-z

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   5.351


  18 in total

1.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.

Authors:  S H Downs; N Black
Journal:  J Epidemiol Community Health       Date:  1998-06       Impact factor: 3.710

2.  Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk.

Authors:  Alison Luk Young; Phyllis N Butow; Paul Rhodes; Katherine M Tucker; Rachel Williams; Emma Healey; Claire E Wakefield
Journal:  J Genet Couns       Date:  2019-01-29       Impact factor: 2.537

3.  Outcomes of a randomised controlled trial of a complex genetic counselling intervention to improve family communication.

Authors:  Jan Hodgson; Sylvia Metcalfe; Clara Gaff; Susan Donath; Martin B Delatycki; Ingrid Winship; Loane Skene; MaryAnne Aitken; Jane Halliday
Journal:  Eur J Hum Genet       Date:  2015-07-01       Impact factor: 4.246

4.  How to support cancer genetics counselees in informing at-risk relatives? Lessons from a randomized controlled trial.

Authors:  Willem Eijzenga; Eveline de Geus; Cora M Aalfs; Fred H Menko; Rolf H Sijmons; Hanneke C J M de Haes; Ellen M A Smets
Journal:  Patient Educ Couns       Date:  2018-05-08

5.  Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch Syndrome.

Authors:  Katja I Aktan-Collan; Helena A Kääriäinen; Eeva M Kolttola; Kirsi Pylvänäinen; Heikki J Järvinen; Ari H Haukkala; Jukka-Pekka Mecklin
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

6.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.

Authors:  Lorelei A Mucci; Jacob B Hjelmborg; Jennifer R Harris; Kamila Czene; David J Havelick; Thomas Scheike; Rebecca E Graff; Klaus Holst; Sören Möller; Robert H Unger; Christina McIntosh; Elizabeth Nuttall; Ingunn Brandt; Kathryn L Penney; Mikael Hartman; Peter Kraft; Giovanni Parmigiani; Kaare Christensen; Markku Koskenvuo; Niels V Holm; Kauko Heikkilä; Eero Pukkala; Axel Skytthe; Hans-Olov Adami; Jaakko Kaprio
Journal:  JAMA       Date:  2016-01-05       Impact factor: 56.272

7.  Patient communication of cancer genetic test results in a diverse population.

Authors:  Charité N Ricker; Rachel B Koff; Chenxu Qu; Julie Culver; Duveen Sturgeon; Kerry E Kingham; Katrina Lowstuter; Nicolette M Chun; Courtney Rowe-Teeter; Alexandra Lebensohn; Peter Levonian; Katlyn Partynski; Karlena Lara-Otero; Christine Hong; Iva M Petrovchich; Meredith A Mills; Anne-Renee Hartman; Brian Allen; Uri Ladabaum; Kevin McDonnell; James M Ford; Stephen B Gruber; Allison W Kurian; Gregory E Idos
Journal:  Transl Behav Med       Date:  2018-01-29       Impact factor: 3.046

8.  Quantifying family dissemination and identifying barriers to communication of risk information in Australian BRCA families.

Authors:  Emma Healey; Natalie Taylor; Sian Greening; Claire E Wakefield; Linda Warwick; Rachel Williams; Kathy Tucker
Journal:  Genet Med       Date:  2017-05-11       Impact factor: 8.822

9.  Examining intrafamilial communication of colorectal cancer risk status to family members and kin responses to colonoscopy: a qualitative study.

Authors:  Kaitlin M McGarragle; Crystal Hare; Spring Holter; Dorian Anglin Facey; Kelly McShane; Steven Gallinger; Tae L Hart
Journal:  Hered Cancer Clin Pract       Date:  2019-06-26       Impact factor: 2.857

10.  When to break the news and whose responsibility is it? A cross-sectional qualitative study of health professionals' views regarding disclosure of BRCA genetic cancer risk.

Authors:  Alison Luk Young; Phyllis N Butow; Katherine M Tucker; Claire E Wakefield; Emma Healey; Rachel Williams
Journal:  BMJ Open       Date:  2020-02-25       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.